BiotechTube

Ethambutol hydrochloride + Clarithromycin + Azithromycin

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mycobacterium Avium-intracellulare Infection

Conditions

Mycobacterium Avium-intracellulare Infection, HIV Infections

Trial Timeline

— → —

NCT ID
NCT00002140

About Ethambutol hydrochloride + Clarithromycin + Azithromycin

Ethambutol hydrochloride + Clarithromycin + Azithromycin is a phase 3 stage product being developed by Pfizer for Mycobacterium Avium-intracellulare Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00002140. Target conditions include Mycobacterium Avium-intracellulare Infection, HIV Infections.

What happened to similar drugs?

3 of 7 similar drugs in Mycobacterium Avium-intracellulare Infection were approved

Approved (3) Terminated (1) Active (3)
✅clarithromycin, rifabutinPfizerApproved
✅AzithromycinPfizerApproved
✅Azithromycin + Rifabutin/rifampinPfizerApproved
🔄ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3
🔄ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)InsmedPhase 3
🔄LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3
❌RHB-204 + PlaceboRedHill BiopharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00002140Phase 3Completed

Competing Products

20 competing products in Mycobacterium Avium-intracellulare Infection

See all competitors
ProductCompanyStageHype Score
TrifluridineAmgenPre-clinical
26
clarithromycin, rifabutinPfizerApproved
43
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerApproved
43
TigecyclinePfizerPhase 2
35
Azithromycin + Rifabutin/rifampinPfizerApproved
43
ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3
37
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)InsmedPhase 3
37
LAI plus multi-drug regimenInsmedPhase 2
32
Liposomal amikacin for inhalation (LAI) + placeboInsmedPhase 2
32
LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3
37
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + RifabutinInnovivaPhase 2
36
Molgramostim nebulizer solutionSavaraPhase 2
21
Inhaled molgramostim + Antimycobacterial regimenSavaraPhase 2
29
Epetraborole + Epetraborole + Placebo + PlaceboAN2 TherapeuticsPhase 2
32
SPR720 + Placebo + Open-label Standard of CareSpero TherapeuticsPhase 2
17
RHB-204 + PlaceboRedHill BiopharmaPhase 3
22